Rituximab is an antibody that binds to B-lymphocytes and is increasingly used during pregnancy. As an immunoglobulin G, it will transfer across the placenta. Previous case reports describe a diversity of clinical presentations in neonates born following rituximab exposure in utero. Our case is the first to offer the long-term experience in the care of an infant with severe neutropenia and prolonged profound hypogammaglobulinemia and class-switching B cell defect after in utero rituximab exposure.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MPH.0000000000001871 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!